I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation tyrosine kinase inhibitor (TKIs). The T315I mutant form of BCR-ABL is the most common mutation that confers resistance to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Congying, Zhang, Lei, Xu, Yun, Ma, Xiangyu, Chen, Peilei, Chen, Zhe-Sheng, Wei, Liuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130674/
https://www.ncbi.nlm.nih.gov/pubmed/37124196
http://dx.doi.org/10.3389/fphar.2023.1183052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130674/
https://www.ncbi.nlm.nih.gov/pubmed/37124196
http://dx.doi.org/10.3389/fphar.2023.1183052

Ejemplares similares